Insilico Medicine has introduced the PandaOmics Box, an on-premise hardware platform designed to enhance drug discovery and research while ensuring maximum data privacy and security.
The PandaOmics Box integrates Insilico’s generative biology AI software, extensive scientific database, and advanced hardware system, enabling biological analytics, target identification, biomarker discovery, and advanced research in personalized medicine and drug discovery without the need for internet access. This feature addresses privacy concerns by allowing operations in a completely offline mode.
The platform utilizes more than 20 predictive models and includes a comprehensive collection of transcriptomics, genomics, epigenomics, proteomics, single-cell data, and compound information. This supports efficient target ranking, analysis, and filters, facilitating more streamlined research.
Enhanced by a local Large Language Model (LLM), the PandaOmics Box also features:
- ChatPandaGPT: Enables researchers to interact with Insilico’s knowledge graph database using natural language.
- Gene-Disease Report: Automatically generates detailed reports on specific research areas.
- Paper Drafting Tool: Assists researchers in creating structured draft papers.
The system’s OpenAPI framework provides bioinformatics access to PandaOmics’ database and AI algorithms, allowing researchers to conduct custom analyses and develop innovative methods.
Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine, highlighted the importance of secure data handling. “Medical and biological data must be secure. A device that operates offline with on-chip confidential computing provides the highest level of security. The PandaOmics Box allows hospitals, institutes, and biotech companies to leverage their data without risking privacy breaches. This supports cutting-edge research in target identification, biomarker discovery, and more.”